| چکیده انگلیسی مقاله |
Background: Cancer is a serious global health issue, and as multimodal therapies have advanced, treatment-related toxicities have a significant influence on function, compliance, and quality of life. Integrative oncology looks for supportive treatment and resilience-promoting supplementary techniques that are supported by research. Rasayana is the rejuvenating branch of Ayurveda that emphasizes on ojas (vitality), immunological balance, and metabolic homeostasis. It is probably useful for cancer care.
Objective: To integrate the safety considerations, emerging clinical cues, conceptual rationale, and implementation pathways of Rasayana-concordant botanicals and regimens as cancer care-modifying adjuncts.
Methods: Using iterative PubMed, Cochrane, EMBASE, AYUSH Portal, ctri.nic.in, ClinicalTrials.gov and WHO ICTRP searches until August 2025, a review was conducted in accordance with SANRA principles. Human clinical and translational data on Rasayana-compatible therapies given in addition to conventional oncologic treatments were, with focus on symptom clusters, safety, mechanistic plausibility, and herb–drug interactions. Classical Ayurvedic terms (e.g., Medhya, Balya, Ojovardhaka, and Raktaprasadana) were linked to their biological correlates and patient-reported outcomes using thematic data synthesis.
Results: Major Rasayana herbs with immunomodulatory, antioxidant, neuroendocrine, and mucosal-protective properties include Withania somnifera, Curcuma longa, Phyllanthus emblica, Tinospora cordifolia, and Ocimum tenuiflorum. Preliminary clinical data indicate improvements in symptoms. Safety themes highlight the importance of product authentication, pharmacovigilance, and monitoring potential herb-drug interactions, particularly those involving CYP3A4 and P-gp regulation.
Conclusion: In integrative oncology, Rasayana-based therapies show early supportive care and physiologically believable potential. Under multidisciplinary supervision, their usage should continue to be customized, safety-monitored, quality-assured, and adjunctive. Well-planned, oncology-focused clinical trials are required. |
| نویسندگان مقاله |
| Himani Sharma
Department of Shalakya Tantra, Sanjeevani Ayurvedic Medical College, Gajraula, Uttar Pradesh, India.
| Raja Ram Mahto
Department of Kayachikitsa, All India Institute of Ayurveda, New Delhi, India.
| Sudhanshu Kumar Jha
Centre for Integrative Oncology, All India Institute of Ayurveda, New Delhi, India.
| Sonam Chauhan
Department of Kayachikitsa, All India Institute of Ayurveda, New Delhi, India.
| Prachi Khandelwal
Department of Kayachikitsa, All India Institute of Ayurveda, New Delhi, India.
| Sanjay Kumar Tiwari
Department of Kayachikitsa, All India Institute of Ayurveda, New Delhi, India.
|